The LKB1/STK11 tumor suppressor encodes a serine/threonine kinase which coordinates cell growth, polarity, motility, and metabolism. In non-small cell lung cancer, LKB1 is somatically inactivated in 25-30% of cases, often concurrently with activating KRAS mutation. Here, we employed an integrative approach to define novel therapeutic targets in KRAS-driven LKB1 mutant lung cancers. High-throughput RNAi screens in lung cancer cell lines from genetically engineered mouse models driven by activated KRAS with or without coincident Lkb1 deletion led to the identification of Dtymk, encoding deoxythymidylate kinase which catalyzes dTTP biosynthesis, as synthetically lethal with Lkb1 deficiency in mouse and human lung cancer lines.
INTRODUCTION
LKB1/STK11 functions as a master regulator of cell metabolism and energy stress responses (1, 2) . Its best characterized target is AMP-activated protein kinase (AMPK), which, is directly phosphorylated and activated by LKB1 in context of low cellular ATP levels (2) . AMPK in turn modulates nutrient utilization to restore energy homeostasis through phosphorylation of multiple substrates controlling nutrient uptake and metabolism (1, 2) . LKB1 also activates other members of AMPK-related family of kinases, which regulate diverse aspects of cell metabolism, growth, and polarity (1, 2) . LKB1/STK11 deficiency results in broad defects in metabolic control, as evidenced by primary cells and cancer cell lines lacking LKB1 being sensitized to nutrient deprivation and other types metabolic stress (3) (4) (5) . LKB1 is also a major tumor suppressor which is somatically inactivated in many common types of cancer (3, 4) . Human tumor data and genetic studies in mice suggest LKB1 mutant cancers are biologically distinct from those with LKB1 intact (6). Notably, Lkb1 inactivation is the single most prominent biomarker for poor outcome in cervical cancer, predicting a survival of 1 year, as compared to a 10 year survival for Lkb1 wild type tumors (7). In mouse models of lung cancer and melanoma, Lkb1 loss synergizes with active KRAS to drive a highly metastatic phenotype not seen in the context of other combinations of mutations (6, 8) . Unfortunately, there are currently few drugs available for clinical use that target LKB1 loss specifically, and recent human cancer cell line screens using >130 drugs under clinical and preclinical investigation failed to identify known anti-cancer agents with strong selective activity in this subset of tumors (data not shown) (9) .
Here, we sought to employ an integrative program to systematically identify novel drug targets in LKB1 mutant lung cancer using synthetic lethal RNAi screen and comprehensive metabolomics analysis. For these studies, we took advantage a series of low passage lung cancer
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on January 27, 2018. © 2013 American Association for Cancer cancerdiscovery.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 7 cell lines derived from genetically engineered mouse models programmed with common mutations in KRAS and p53, alone or in combination with LKB1. Whereas the heterogeneity of human cancer cell lines can obscure synthetic lethal associations, we predicted this murine cell line panel developed in the context of a well-defined model system, would effectively enable discovery of genotype-driven sensitivities.
RESULTS

Generation of lung cancer cell lines from GEMMs
To generate isogenic lung cancer cell lines, somatic KRAS activation and p53 loss with or without LKB1 inactivation were induced in the lungs of genetically engineered mice (Kras
) by intranasal administration of Adenovirus-Cre as previously described (6). Inactivation of p53 was included in these models as inactivation of p53 is common in human NSCLC (>50%) (10) . Tumor nodules from mice of defined genotypes were dissected, minced and cultured, resulting in the derivation of the 634, 855, and 857 lines from
mice (Lkb1-wt) and the t2, t4, and t5 lines from Kras
To identify genes that induce cell death selectively in Lkb1-null lung cancers, a synthetic lethal screen was performed using a pooled 40K murine shRNA lentiviral library with each of the Lkb1-wt and Lkb1-null cell lines. The relative abundance of shRNAs in each cell line sample was determined by deep-sequencing, and for every shRNA, a log2 fold change (log2FC) value was calculated from the difference in relative abundance at a late time point after infection versus the initial shRNA-infected sample. Unsupervised hierarchical clustering analysis of the ranked hairpins from the triplicate pooled shRNA library screens revealed clear clustering of the Lkb1-wt and Lkb1-null cells into distinct groups, and the blue-color in the top-right corner represents genes for which the abundance of shRNAs is significantly reduced in all Lkb1-null cultures, suggesting a specific effect in the inhibition of Lkb1-null cell growth (Fig. 1A) . We collapsed the ranked hairpins using two methods, a RIGER analysis (KS t-test based statistics) and a weighted second-best analysis to rank genes that selectively impaired proliferation/viability in Lkb1-null cells. We nominated a union of 344 genes, identified by the top 100 individual hairpins for 88 genes (Supplementary Table S1 .1) and the top 200 genes from both the KS (Supplementary   Table S1 .2) and weighted-second best analysis (Supplementary Table S1. 3), as our initial prioritized list (Fig. 1B) 
Metabolomics analysis implicates Dtymk as critical gene in Lkb1-null cells
LKB1 is reported to be involved in metabolic reprogramming (4, 11), we therefore assessed the metabolic profile of Lkb1-wt and Lkb1-null cells and discovered a set of 58 metabolites, including nucleotide metabolites IMP, AMP, ADP, GMP, dGMP, UMP, UDP, CDP, dCDP, and dTDP, that were present at consistently lower levels in Lkb1-null cells (Fig. 1D) . Pathway enrichment analysis demonstrated that metabolites in both purine and pyrimidine metabolism were significantly reduced in Lkb1-null compared to Lkb1-wt cells ( , respectively), including multiple metabolites involved in dTTP synthesis such as dTDP (the product of DTYMK) and UDP/CDP/dCDP (products of CMPK) ( Fig. 1E) (12, 13) .
Collectively, these two independent sets of data suggest that Lkb1 mutant lung cancer cells exhibit alterations in dTTP metabolism and are particularly sensitized to disruption of intracellular dTTP synthesis, and therefore have potential as important targets in Lkb1-null lung cancer.
Dtymk is synthetic lethal gene selectively required for Lkb1-null cell proliferation
To further examine the role of DTYMK in lung tumorigenesis, we screened 5 shDtymks and identified shDtymk-1 and shDtymk-3 knocking down DTYMK to nearly undetectable levels (Supplementary Fig. S2A and Table S2 ). Compared to shGFP, both shDtymk-1 and shDtymk-3 strongly inhibited the growth of the Lkb1-null (t2, t4, and t5), while producing a weaker effect in the Lkb1-wt (634, 855, and 857) cell lines ( Fig. 2A and Supplementary Fig. S2B ). To see if overexpression of shRNA-resistant Dtymk can rescue shDtymk effect, Dtymk-R1 and Dtymk-R3 were cloned into pLenti6 vector and then transduced into Lkb1-null t4 cells. Blasticidin-resistant cells were pooled and further transduced with shGFP, shDtymk-1, or shDtymk-3, respectively.
Consistently, shDtymk-1 and shDtymk-3 killed Lkb1-null t4 cells within 3 days, whereas Dtymk-R1 and Dtymk-R3 expression largely restored the growth of shDtymk-1 and shDtymk-3 transduced t4 cells (Fig. 2B) . Western blot analysis revealed lower DTYMK signals in t4-Dtymk-R1/shDtymk-1 and t4-Dtymk-R3/shDtymk-3 cells, suggesting that some of the blasticidinresistant cells were not DTYMK-R positive and thus were killed by shDtymk (Fig. 2B) , which likely accounted for the significant but incomplete rescue by Dtymk-R1 or Dtymk-R3. To extend these findings to tumorigenesis in vivo, Lkb1-wt (634 and 857) and Lkb1-null (t2 and t4) cells were transduced with doxycycline-inducible (TetOn) shGFP or shDtymk-3 and then implanted into athymic nude mice. Consistent with the in vitro proliferation assay, doxycycline-induced expression of shDtymk-3 for 3 weeks resulted in a marked impairment in the growth of Lkb1-null tumors while producing more modest effects in the Lkb1-wt tumors (Fig. 2C ).
Dtymk knockdown alters pyrimidine metabolism
DTYMK catalyzes the phosphorylation of dTMP to form dTDP, and it is the first merged step of both the de novo and salvage pathways in the production of dTTP (Fig. 1E) . We expected that knockdown of Dtymk would inhibit this pathway and lead to accumulation of the substrate dTMP and decrease of the product dTDP. Corresponding metabolite analysis of Lkb1-wt 634 and Lkb1-null t4 cells transduced with shDtymk-1 revealed the expected significant increase in dTMP and moderate decrease in dTDP levels in both cell lines (Fig. 2D) , indicating that DTYMK is a major source of dTDP in the cells and underscores the importance of this gene in cancer cell proliferation, as dTDP is required for production of dTTP for DNA synthesis. To investigate whether adding dTTP to the medium can rescue shDtymk-induced cell death, Lkb1-wt 634 and Lkb1-null t4 cell lines were transduced with shGFP, shDtymk-1, or shDtymk-3 and cultured in the presence or absence of 100 M dTTP for 4 days (14) . Consistently, shDtymk-1 and shDtymk-3 killed more Lkb1-null t4 than Lkb1-wt 634 cells; but not the cells cultured in medium containing exogenous dTTP ( Fig. 2E ; confirmation of Dtymk knockdown and incorporation of the exogenous dTTP into DNA are shown in Supplementary Fig. S3A and S3B).
Collectively, our data indicate that dNTP metabolism is impaired in Lkb1-deficient lung cancer cells, and that targeting Dtymk is synthetically lethal in this setting.
Lkb1-null cells are more prone to DNA damage than Lkb1-wt cells
Knockdown of Dtymk will consequently reduce dTTP but also increase dUTP levels. Such Knockdown of Dtymk shortly (i.e. 2.5 days post shDtymk-transduction) resulted in comparable increases in the phosphorylation of CHEK1 and H2AX in both cell types, whereas the phosphorylation of RPA32 was much more pronounced in Lkb1-null cells (Fig. 3A) , suggesting more DNA damage and elevation in nucleotide excision repair in Lkb1-null cells (23).
Interestingly, the expression of total RPA32 was increased in Lkb1-wt cells (Fig. 3A) , suggesting that LKB1 may positively regulate RPA32 expression following Dtymk knockdown and more DNA damage. Collectively, these data suggest that Lkb1 loss sensitizes cells to DTYMKdepletion induced DNA damage and replication stress, as equivalent knockdown of Dtymk in Lkb1-null and Lkb1-wt cells leads to more robust DNA damage in the Lkb1-null cell lines.
DNA replication is more sensitive to Dtymk knockdown in Lkb1-null than in Lkb1-wt cells
To examine how the knockdown of Dtymk affects DNA synthesis, Lkb1-wt and Lkb1-null cells were pulse-labeled with IdU for 20 min at 0, 2.5, and 3.5 days post-transduction with shDtymk-1. We further sought to determine whether our observations in mouse lung cancer cells could be recapitulated in human LKB1-deficient NSCLC cell lines. We first screened 5 shRNAs targeting DTYMK and identified two, shDTYMK-D8 and shDTYMK-D10, gave efficient knockdown ( Supplementary Fig. S6A and Table S2 ). Next we screened LKB1-wt and LKB1-deficient NSCLC cell lines (Fig. 4A) for proliferation in response to DTYMK knockdown and found that LKB1-deficient H2122 and A549 cell lines had heightened sensitivity as compared to LKB1-wt H358 and Calu-1 cell lines (Fig. 4B) . Knockdown of DTYMK was confirmed by Western blot (Fig. 4C) . shDTYMK-D10 transduction demonstrated an increased lethality in LKB1-wt H358
and Calu-1 cells, trending towards that of the LKB1-deficient cell lines (Fig. 4B) . One possible explanation could involve a differential threshold of DTYMK knockdown, as the remaining DTYMK protein levels after shDTYMK-D10 transduction were lower than that of shDTYMK-D8 (Fig. 4C ). This suggests that there may be a differential sensitivity to absolute DTYMK reduction between LKB1-deficient and LKB1-wt cells. DTYMK was reported to be synthetic lethal with doxorubicin in colon cancer cells independent to p53 (28). Consistently, the synthetic lethal interaction of LKB1-deficient and DTYMK knockdown may be independence to p53 status, as LKB1-deficient cell lines with (A549) or without functional p53 (H2122) behave similarly (Fig. 4B ).
Next we showed that knockdown of DTYMK in A549 cells reduced dTDP levels (Fig. 4D) , suggesting DTYMK is a major source of dTDP in human lung cancer cells. We further showed that LKB1-deficient H2122 and A549 were more sensitive than LKB1-wt H358 and Calu-1 cell lines to the treatment with the selected CHEK1 inhibitors (Fig. 4E and Supplementary Fig. S4B Fig. S6B ).
DISCUSSION
In the current study, we create cell lines using Lkb1-null lung tumor nodules and performed multiple screens that identified Dtymk as putative synthetic lethal candidate with Lkb1 loss. Human DTYMK was cloned by functional complementation of a Saccharomyces cerevisiae cell cycle mutant cdc8, an essential gene for DNA synthesis (29) . DTYMK is the first enzymatic step following the convergence of the de novo and salvage pathways in dTTP biosynthesis. In the de novo pathway, the DTYMK substrate dTMP is synthesized from methylation of dUMP by thymidylate synthase (TS). In the salvage pathway, dTMP is produced from phosphorylation of thymidine by thymidine kinase (TK). The next step in both pathways is the DTYMK-mediated phosphorylation of dTMP to form dTDP (30, 31) . The production of dTDP is in contrast to that of the other deoxyribonucleotides used in DNA synthesis-dADP, dGDP, dCDP, and dUDP, which are synthesized from ADP, GDP, CDP, and UDP by ribonucleotide reductase (12, 32) . Therefore, the unique dTTP biosynthesis pathway made itself good targets for drugs. There are multiple precedents of inhibition of the key enzymes in the de novo dTTP synthesis pathway, including thymidylate synthase by 5-fluorouracil or pemetrexed (15) and ribonucleotide reductase by hydroxyurea (33) . We have targeted TS and ribonucleotide reductase in both the mouse and human NSCLC Lkb1/LKB1 cell lines using the same drugs and have not seen any selective effect on Lkb1/LKB1-deficient cell growth, likely because of an escape mechanism from the salvage pathway ( Supplementary Fig. S9 ). In summary, the lack of redundant pathways for dTTP biosynthesis and the vital role of DTYMK in this process together make DTYMK a new anti-cancer target. In this regard, expression of DTYMK is increased in the majority of lung adenocarcinomas in comparison to normal lung ( Supplementary Fig. S10A ), and elevated DTYMK levels are correlated with poorer survival (Supplementary Fig. S10B ). Unfortunately, LKB1 mutation status was not determined in these data sets.
In addition to identifying DTYMK as a potential therapeutic target for LKB1-deficient lung cancer, we have also provided proof of principle that GEMM-derived cancer cell lines can provide a genetically homogeneous and therefore tractable substrate for high-throughput screens to identify novel therapeutic targets. To date, the weakness of genome-wide RNAi screening has been high false discovery rates and cell line-specific off-target effects, and consequently, despite the implementation of multiple very large scale cell line screening programs, few actionable genotype-associated sensitivities have been uncovered to date. Our study suggests that integrating RNAi screening with metabolite profiling is an effective strategy to leverage the strengths and mitigate the weaknesses of each approach. We propose that this approach will have broad applicability, and enable more rapid development of additional targeted therapeutics for an array of genetic abnormalities occurring in cancer.
METHODS
Detailed protocols for all sections are described in Supplementary Methods.
RNAi screening and metabolite profiling
Research. Large-scale pooled screening and data analysis were performed at the Broad Institute's RNAi Platform as recommended (34) , and metabolite extraction and targeted mass spectrometry analysis were performed as reported (35, 36) .
Cell lines and cell culture
Fresh murine lung tumor nodules were minced and cultured in 100 mm dishes with RPMI 1640/10% FBS/1% pen-strep. Calu-1, H358, H2122, and A549 (obtained from ATCC) were cultured in 1640/10% FBS/1% pen-strep; and 293ft (Invitrogen) was cultured in DMEM/10% FBS/1% pen-strep. All cells were cultured at 37 o C in a humidified incubator with 5% CO 2 .
Plasmid constructs and mutagenesis
pLKO.1-shRNAs were purchased from Broad Institute. DTYMK (BC030178) cDNAs was purchased from Thermo Scientific. ShRNA-resistant DTYMKs were made by mutagenesis PCR and subcloned into the BamH I and XhoI sites of pLenti6 vector (Invitrogen). All mutagenized cDNAs were confirmed by sequencing.
Multiple routine in vitro studies
Lentiviral production and target cell transduction, proliferation assay, RT-qPCR, Western blot, flow cytometry, and immunofluorescence microscopy were performed as described in the Supplementary Methods.
In vivo study
Lkb1-wt and Lkb1-null cells were transduced with pTetOn-shGFP (puro) or pTetOn-shDtymk-3 (puro) and then 1 million of puro-resistant cells per transduction were implanted into athymic 
